No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Eva Medtec Advises Breakthrough Neuroglide™ Pain Relief & Recovery System Receives Reimbursement From Workers’ Comp Insurance for Patients with Back/Neck Pain

Editor: What To Know

  • has announced in addition to ongoing over-the-counter sales and clinician referrals, they are also accepting prescriptions for their innovative Neuroglide system for patients who have back/neck pain related to a workers’.
  • Compensation insurance companies must then give Eva Medtec prior authorization in order for a patient to receive a Neuroglide system.
  • “We are so pleased that recipients are seeing improvements in their back and neck pain thanks to Neuroglide—and we’re excited that physicians are recognizing the impact that our device can have on their patients’.

Eva Medtec, Inc. has announced in addition to ongoing over-the-counter sales and clinician referrals, they are also accepting prescriptions for their innovative Neuroglide system for patients who have back/neck pain related to a workers’ compensation claim.

The patented, FDA-cleared Neuroglide Back/Neck Pad is the first of a system of automated therapy devices that provide effective, convenient, and sustainable pain management solutions for at-home use.

The technology is designed to emulate a therapeutic modality called manual lymphatic drainage (MLD). MLD triggers the body’s parasympathetic nervous system, activating powerful natural relaxation and pain relief pathways.

“We are so pleased that recipients are seeing improvements in their back and neck pain thanks to Neuroglide—and we’re excited that physicians are recognizing the impact that our device can have on their patients’ pain levels,” says Neuroglide inventor and Eva Medtec founder Irene Waldridge.

Workers’ compensation insurance companies must then give Eva Medtec prior authorization in order for a patient to receive a Neuroglide system.

Note: insurance companies approve the Neuroglide system on a case-by-case basis. Not all claims are guaranteed to be approved. Approval for prior authorization is not guaranteed.

Neuroglide inventor Irene Waldridge previously founded Tactile Medical where she held four patents as the inventor of the Flexitouch® System for the treatment of lymphedema and venous insufficiency.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy